Panacea-ml
Explainable-AI Platform to Streamline Clinical Trial Design
Company Overview
Snapshot
Founded in August 2022 by Prof. Boaz Lerner, Panacea-ml operates with 1–10 employees. The company has secured funding across one round from Sanara Ventures and the Israel Innovation Authority. In November 2022, Panacea-ml received funding from Sanara Ventures and the Israel Innovation Authority.
Business overview
Panacea-ml is a Health Tech & Life Sciences company that develops an Explainable AI platform designed to streamline clinical trial design. Spun out of Ben Gurion University, the company's cutting-edge SaaS platform leverages proprietary explainable AI and causal discovery theory to uncover causal relationships between clinical markers, disease progression, and drug responses. This technology aims to de-risk, accelerate, and optimize trial designs, providing transparent and clinically relevant insights. Panacea-ml targets the data analytics and design segment of the clinical trial market, focusing on high-failure areas such as neurology and immuno-metabolic diseases.
Strategic signal
In July 2024, Panacea-ml completed the PharmStars accelerator program, marking its position as the first Israeli startup to graduate from the program. This achievement signals strong validation of Panacea-ml's Explainable AI platform within the pharmaceutical industry, indicating its readiness for broader market adoption and potential for strategic partnerships in digital health.
Log in to access full profile ›Company Intelligence Q&A
- When was Panacea-ml founded and by whom?
- Panacea-ml was founded in August 2022 by Prof. Boaz Lerner.
- What is Panacea-ml's core technology?
- Panacea-ml's core technology is an Explainable AI platform that utilizes causal discovery theory and proprietary graphical models to provide transparent, clinically-relevant insights into clinical trial outcomes, enhancing predictive accuracy and trial success rates.
- Which accelerator programs has Panacea-ml completed?
- In July 2024, Panacea-ml completed the PharmStars accelerator program, becoming the first Israeli startup to graduate from it. Additionally, in April 2024, the company completed the first cohort of the SHAAR-Shaare Zedek - Arieli Healthcare innovation hub.
- What markets does Panacea-ml target?
- Panacea-ml targets the $6 billion Data Analytics and Design segment of the clinical trial market, with a focus on high-failure areas such as neurology and immuno-metabolic diseases, across global markets including the United States, Japan, and Germany.